1. Medicines and Healthcare Products Regulatory Agency(2020).New guidance and information for industry from the MHRA.https://www.gov.uk/government/collections/new-guidance-and-information-for-industry-from-the-mhra(accessed 27 September 2021).
2. Assessing the Safety of Glucose-Lowering Drugs — A New Focus for the FDA
3. National Institute for Health and Care Excellence (NICE)(2016).Technology appraisal guidance [TA390]: canaglilfozin dapagliflzoin and empagliflozin as monotherapies for treating type 2 diabetes.https://www.nice.org.uk/guidance/ta390(accessed 27 March 2021).